Apace Packaging Recalls Acyclovir

News
Article

The company is voluntarily recalling one lot of Acyclovir Tablet due to packaging that may contain a different product.

Apace Packaging LLC announced on Feb. 13, 2018 that it was voluntarily recalling one lot of Acyclovir Tablet, USP, 400mg, 50ct Unit Dose to the retail level because some packages may contain Torsemide, 20mg tablets. The affected lot, number 19900, has an expiration date of May 2019 and was distributed to R&S Northeast and nationwide.

The company has not yet received any reports of adverse events associated with the recalled product; however, it says that missing a dose of Acyclovir may cause reactivation of the virus being treated. In additional, unintentional use of Torsemide could cause excessive urination.

Acyclovir is used for the treatment of herpes zoster (shingles), genital herpes, and chickenpox. Torsemide is used to treat edema and hypertension.

Source: FDA

Recent Videos
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.